CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• EPS Net Y/Y Annual
X4 Pharmaceuticals Inc  (NASDAQ: XFOR)
Other Ticker:  
 
 

XFOR's EPS Net Growth by Quarter and Year

X4 Pharmaceuticals Inc's EPS Net results by quarter and year

 



XFOR EPS Net (in $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December - -5.79 -0.30 -7.80
3rd Quarter September - -5.40 -9.90 -18.00
2nd Quarter June - 13.50 -4.80 -21.60
1st Quarter March 1.20 -7.80 -5.51 -37.01
FY   1.20 -5.49 -20.51 -84.41

XFORs Annual EPS Net
X4 Pharmaceuticals Inc's EPS Net in the fiscal year 2024 $ -5.70
X4 Pharmaceuticals Inc's EPS Net in the fiscal year 2022 $ -45.60
X4 Pharmaceuticals Inc's EPS Net in the fiscal year 2021 $ -119.70
X4 Pharmaceuticals Inc's EPS Net in the fiscal year 2020 $ -92.70
X4 Pharmaceuticals Inc's EPS Net in the fiscal year 2019 $ -138.90




XFOR EPS Net first quarter 2025 Y/Y Growth Comment
X4 Pharmaceuticals Inc in the first quarter 2025 achieved EPS Net of $ 1.20 compare to EPS net loss recorded in same quarter a year ago.

According to the results reported in the first quarter 2025, X4 Pharmaceuticals Inc achieved the best EPS Net growth in Biotechnology & Pharmaceuticals industry. While X4 Pharmaceuticals Inc' s EPS Net no change of 0% ranks overall at the positon no. in the first quarter 2025.


XFOR EPS Net ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
X4 Pharmaceuticals Inc's first quarter 2025 EPS Net $ 1.20 XFOR's Income Statement
X4 Pharmaceuticals Inc's first quarter 2024 EPS Net $ -7.80 Quarterly XFOR's Income Statement


XFOR EPS Net (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   - - - -


Go to entire XFOR Income Statement >> Back to XFOR Growth rate Comparisons >>


EPS Net first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

EPS Net Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
EPS Net first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
EPS Net Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

EPS Net by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

X4 Pharmaceuticals Inc's Q/Q EPS Net Growth


EPS Net Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


XFOR's I. Quarter Q/Q EPS Net Comment
Improvement I. Quarter 2025where X4 Pharmaceuticals Inc published EPS Net of $ 1.20 should is starting point of positive performance.X4 Pharmaceuticals Inc announced in the I. Quarter 2025 EPS Net of $ 1.20 compare to EPS net loss recorded in previos quarter.

Within Biotechnology & Pharmaceuticals industry X4 Pharmaceuticals Inc achieved highest sequential EPS Net growth. While X4 Pharmaceuticals Inc's EPS Net growth quarter on quarter, overall rank is .


EPS Net Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
EPS Net Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
EPS Net Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


XFOR's I. Quarter Q/Q EPS Net Comment
Improvement I. Quarter 2025where X4 Pharmaceuticals Inc published EPS Net of $ 1.20 should is starting point of positive performance.X4 Pharmaceuticals Inc announced in the I. Quarter 2025 EPS Net of $ 1.20 compare to EPS net loss recorded in previos quarter.

Within Biotechnology & Pharmaceuticals industry X4 Pharmaceuticals Inc achieved highest sequential EPS Net growth. While X4 Pharmaceuticals Inc's EPS Net growth quarter on quarter, overall rank is .


X4 Pharmaceuticals Inc's 12 Months EPS Net Growth Year on Year


EPS Net TTM Growth

12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)
Cumulative EPS Net 12 Months Ending $ 3.51 $ -0.18 $ 0.00 $ -0.15 $ -0.76
Y / Y EPS Net Growth (TTM) - - - - -
Year on Year EPS Net Growth Overall Ranking # # # # #
Seqeuential EPS Net Change (TTM) - - - - -
Seq. EPS Net Growth (TTM) Overall Ranking # # # # #


Cumulative EPS Net growth Comment
In the Mar 31 2025 period, X4 Pharmaceuticals Inc had cumulative twelve months EPS Net of $ 4 compare to EPS net loss of $ -23 a year ago.

X4 Pharmaceuticals Inc achieved highest trailing twelve month year on year EPS Net growth. While overall EPS Net growth ranking, remained unchanged compare to the previous quarter at no. .

EPS Net TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

EPS Net TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


EPS Net TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative EPS Net growth Comment
In the Mar 31 2025 period, X4 Pharmaceuticals Inc had cumulative twelve months EPS Net of $ 4 compare to EPS net loss of $ -23 a year ago.

X4 Pharmaceuticals Inc achieved highest trailing twelve month year on year EPS Net growth. While overall EPS Net growth ranking, remained unchanged compare to the previous quarter at no. .


EPS Net TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

EPS Net TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS Net TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other EPS Net Growth
Biotechnology & Pharmaceuticals Industry EPS Net Growth Trends and Statistics
Healthcare Sector EPS Net Growth Statistics
EPS Net Growth Trends for overall market
XFOR's EPS Net Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking EPS Net Growth
Lowest Ranking EPS Net Growth
EPS Net Growth for XFOR's Competitors
EPS Net Growth for X4 Pharmaceuticals Inc's Suppliers
EPS Net Growth for XFOR's Customers

You may also want to know
XFOR's Annual Growth Rates XFOR's Profitability Ratios XFOR's Asset Turnover Ratio XFOR's Dividend Growth
XFOR's Roe XFOR's Valuation Ratios XFOR's Financial Strength Ratios XFOR's Dividend Payout Ratio
XFOR's Roa XFOR's Inventory Turnover Ratio XFOR's Growth Rates XFOR's Dividend Comparisons



Companies with similar EPS Net no change for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %EPS Net for the quarter ending Mar 31 2025
Mettler Toledo International Inc-5.22%$ -5.218 
Pfizer Inc-5.45%$ -5.455 
Labcorp Holdings Inc -6.32%$ -6.320 
Abbvie Inc -6.49%$ -6.494 
National Research Corporation-7.41%$ -7.407 
Align Technology inc -8.63%$ -8.633 
Iqvia Holdings Inc -10.26%$ -10.256 
Utah Medical Products Inc-15.60%$ -15.596 
Ani Pharmaceuticals Inc-15.85%$ -15.854 
Mimedx Group Inc -16.67%$ -16.667 
Stryker Corp-17.56%$ -17.561 
Carlisle Companies Incorporated-19.40%$ -19.395 
Embecta Corp -20.00%$ -20.000 
West Pharmaceutical Services Inc -20.65%$ -20.645 
Davita Inc -24.53%$ -24.528 
Dexcom Inc -25.00%$ -25.000 
Envista Holdings Corporation-28.57%$ -28.571 
Dariohealth Corp -30.00%$ -30.000 
Insulet Corporation-31.51%$ -31.507 
Corcept Therapeutics Inc-32.00%$ -32.000 
Amphastar Pharmaceuticals Inc -37.04%$ -37.037 
Alkermes Plc -38.10%$ -38.095 
Biogen Inc -39.26%$ -39.259 
Vertex Pharmaceuticals Inc-40.86%$ -40.855 
Select Medical Holdings Corp-41.33%$ -41.333 
Becton Dickinson And Company-42.16%$ -42.162 
Solventum Corporation-43.07%$ -43.066 
Lantheus Holdings Inc -45.45%$ -45.455 
Pacira Biosciences inc -47.37%$ -47.368 
Organon and Co -57.69%$ -57.692 


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com